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Introduction
Next generation DNA sequencers have substantially expanded
our ability to survey human genomes for germline variants or the
somatically acquired mutations characteristic of cancer [1,2,
3,4,5,6]. For many research studies and applications, targeted
resequencing of specific genomic regions such as candidate
genes, is a generally useful approach for validating mutations in
newly discovered disease genes, detecting rare variants from
populations and screening for polymorphisms of interest. While
exome sequencing has become commonly available, there are
numerous applications and studies which oftentimes only
require a significantly smaller scale of targeted resequencing.
Examples of informative subsets of genes include mutation
analysis of Mendelian disorder genes with extensive genetic
heterogeneity. For example, there are over forty causative genes
for hypertrophic cardiomyopathy but clinical testing is restrict-
ed to only a small number of these genes for a given clinical
analysis [7]. Another application is for the follow up validation
of somatic mutations in cancer genes sets identified from exome
surveys of large collections of tumors [8,9]. Frequently there is a
requirement for additional validation of mutations from subsets
of candidate cancer genes to confirm that mutations are not
simply passenger mutations with no significant biological or
clinical significance. Genome wide association studies involving
thousands of individuals are increasingly being geared towards
resequencing specific loci for the identification of rare variants
and would be facilitated by high throughput approaches for
capturing specific loci [10]. For the validation of large number
of variants identified in complete genome or exome surveys,
validation targeted resequencing using next generation plat-
forms has proven to be an attractive alternative to Sanger
sequencing.
For those researchers seeking to analyze candidate gene sets
for mutations, polymorphisms and other variants with next
generation sequencers, we have developed a robust approach
using in-solution capture mediated by pools of 80-mer
oligonucleotides. Our capture technology is geared towards
resequencing gene subsets substantially larger than can be done
efficiently with simplex or multiplex PCR but reduced in scale
compared to exome sequencing. This method is highly flexible
as nearly any gene can be targeted and the assay can be
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implemented with standard molecular biology infrastructure in
a short period of time. Nanogram amounts of starting genomic
DNA are all that is required which is significantly less than is
required for commercially available capture assays [11,12]. Our
method has been successfully applied to targets ranging in size
from 100 Kilobases (Kb) to a Megabase (Mb). We also
demonstrated the application of sequence indexing to increase
sample throughput.
To provide optimal flexibility in capturing human gene targets,
we designed an in silico set of oligonucleotides that capture the
gene exons annotated by the Consensus Coding Sequence
(CCDS) Project [13]. We refer to this resource as the Human
OligoExome which is publically available via a website
(oligoexome.stanford.edu). Using oligonucleotide sequences de-
rived for the Human OligoExome, this approach allows
researchers to design capture assays using any arbitrary set of
CCDS annotated exons and subsequently resequence them in
highly multiplexed capture reactions. The in silico set has quality
control features to improve the performance of capturing exons
from the CCDS reference set.
This in-solution method uses selective genomic circularization
to capture specific restriction fragments (Fig. S1) [14]. This
method differs from the molecular inversion probe (MIP)
approach in that the genomic DNA target is directly incorporated
into a circular molecule whereas in MIP technology, the
oligonucleotide is converted to an intact circle through polymerase
extension using the genomic DNA target as a template [15]. The
capture reaction requires a restriction enzyme digest of nanogram
amounts of genomic DNA followed by incubation with a mixture
of two types of oligonucleotides: i) pools of capture oligonucleo-
tides which are specific for a targeted genomic region and ii) a
general vector oligonucleotide. Each capture oligonucleotide is an
80-mer and has two single-stranded target complementary end-
sequences (20 nucleotides each) that are linked by a general
sequence motif (40 nucleotides). For each oligonucleotide, the
complementary flank sequences, referred to as capture arms,
mediate the selective circularization of the genomic DNA target,
which has been cut by a specific restriction enzyme. The universal
vector oligonucleotide is complementary to the general sequence
motif in every targeting oligonucleotide. After annealing and
ligation, the vector sequence is incorporated into the selected
genomic circles. The vector sequence contains a universal primer-
pair that mediates the amplification of all of the targeted genomic
contents of the circle. A next generation sequencer such as the
Illumina Genome Analyzer is used to interrogate the targeted
amplicons.
To demonstrate that this approach can accurately identify
polymorphisms, variants and mutations in targeted regions of the
human genome, we developed several capture assays. We
conducted a targeted resequencing analysis of large numbers of
exons from normal genomic DNA of individuals in the Hapmap
study [16] as well as genomic DNA from a matched normal-
tumor pair. For resequencing of the captured genomic DNA, we
used an Illumina Genome Analyzer. Relying on the Human
OligoExome Resource we designed three different assays that
captured the exons of 10 genes (102.48 Kb total), 96 genes
(822.15 Kb total) and 106 genes (943 Kb total); the last of these
included all of the 96 genes from the second assay. We optimized
the assay to accept starting amounts of genomic DNA under
100 ng. We assessed the performance of the assay and developed
an adjustment scheme to normalize fold-coverage of captured
regions. We successfully integrated indexing to increase sample
throughput post-capture. We also provide a cost assessment of
our capture assay per sample.
Results
Designing capture oligonucleotides for the CCDS exon
set
We designed an automated bioinformatic pipeline that relies
on in silico assessment of different restriction enzymes to create
capture oligonucleotides covering the exons defined by the
CCDS project. We targeted genes as defined by a specific region-
of-interest (ROI), which encompasses exon bases and 50 bases of
adjacent intronic sequence. As our first step in developing this
process, we evaluated the ability of restriction enzymes to
produce intact ROIs. Our initial test set was 244 ROIs from
23 genes. With respect to this method, we ranked the effectiveness
of 14 commercially available restriction enzymes recognizing 12
out of the 16 possible 4-base recognition sites (Text S1).
Restriction enzymes MseI, BfaI, SauIIIA and CviQI had the
highest design coverage, with greater than 95% of the 244 ROIs
covered. We confirmed that these four enzymes ranked highest in
terms of providing optimal design coverage by testing a second,
separate set of 170 ROIs derived from 10 other genes.
Using the four enzymes that provided optimal coverage (MseI,
BfaI, Sau3AI and CviQI) we empirically determined that fragments
of up to 800 bases were efficiently captured. The assay we
previously described targeted 250 base fragments [14]. This
enabled us to design fewer oligonucleotides to cover any given
portion of the targeted genome compared to our previous effort.
Our results are summarized in Table 1. We used 17,049 genes
listed in the CCDS database [13]. The database contains exon
definitions for 16,952 genes. The remaining 97 were under review
at the time of download with no exon definitions. Exon definitions
for these remaining genes came from Genbank. From this set we
extrapolated 157,624 ROIs which were then submitted to the
TargetedOligoDesign program. The availability of restriction sites
and the avoidance of known SNPs appearing in the capture arms
were the main design constraints. A total of 784,783 capture
oligonucleotides were generated in silico in approximately equal
proportions for the four restriction enzymes. We designed capture
oligonucleotides with substantial redundancy to increase the
likelihood that at least one oligonucleotide would capture the
target. These four restriction enzymes provided enough sites to
adequately design capture oligonucleotides which cover over 98%
of ROI bases over all CCDS exons.
We analyzed the sequences of all oligonucleotides’ capture arms
in order to identify potential issues that might cause failures or off-
target capture. Four different quality control factors were reviewed
for each oligonucleotide which included the presence of sequences
repeated over the human genome (W-flag), paralogs (P-flag),
matches to consensus repeats (R-flag) and Alu sequences (A-flag).
We identified a total of 97,120 oligonucleotides with at least one
flag (Table 2). Each enzyme based set contains a relatively similar
number of flagged oligonucleotides. The genome W-flag is the
least restrictive and applies to 96,565 oligonucleotides. We verified
that all of the P-flag oligonucleotides also had a W-flag. More than
90% of the A-flag and R-flag oligonucleotides also had a W-flag.
The small number of differences is attributable to the shorter 14
base sequence used for comparisons in the case of the A and R
flags. We examined the reduction in coverage using the quality
control flags (Table 2). Excluding the flagged oligonucleotides for
all four enzymes provided an average coverage of 94.2% for any
given CCDS annotated gene.
Access to the Stanford Human OligoExome
We deposited all 784,783 capture oligonucleotide sequences
into a publically-accessible web-based database application
Highly Multiplexed Targeted Resequencing
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(oligoexome.stanford,edu). Upon arriving at the Human OligoEx-
ome website, new users are initially prompted to sign-up for access.
Subsequently, users will enter their username and password to
access the database. Capture oligonucleotide sequences for specific
genes may be retrieved either by entering one or more genes of
interest in HUGO symbol format, or by electing to download the
set of sequences for the entire exome in a compressed format. The
very small number of genes which are not covered are also listed at
the Human OligoExome website.
Designing custom capture assays
We designed three separate capture assays using three
restriction enzymes for our initial test and these assays are
described in Table 3. We initially selected ten cancer genes
(Text S1) where the ROI bases (combined exons and adjacent
50 bp of intronic sequence) covered a total 48.141 Kb of
sequence. This smaller target size was useful for optimizing the
assay’s molecular performance. We designed and synthesized
360 oligonucleotides using the restriction enzymes MseI, BfaI
and Sau3AI. This 10-gene assay theoretically captures
47.554 Kb of ROI bases (98% of the total) and 54.934 Kb of
additional intronic sequence extending further out from the
exons for a total capture size of 102.488 Kb. Additional intronic
sequences are captured because some capture oligonucleotides
utilize a restriction site that exists outside of the 50 bases of
intronic sequence adjacent to exons. This additional capture is
particularly useful in assessing other genomic regions such as
promoters.
To test larger capture assays, we chose 106 cancer genes
(capture assay 3) derived from two previously identified cancer
gene sets (Text S1). These genes included the top ranked
COSMIC cancer genes as determined by mutation frequency
for colorectal and pancreatic cancer [17]. We also included the top
ranked cancer genes identified for colorectal cancer [8] and
pancreatic cancer [9] from an exome survey of these primary
tumors. This target had a ROI size (exon and adjacent 50b) of
562.974 Kb (Table 3). We extracted 4,792 targeting oligonucle-
otides from the Human OligoExome resource covering these
genes and synthesized these oligonucleotides. This assay relied on
separate MseI, BfaI and CviQI reactions. Including all intronic
sequences, capture assay 3 theoretically targets 943 Kb. The
design captures 512.556 Kb or 91% of the intended ROI bases.
We also report some intermediate results based on a 96-gene assay
(capture assay 2). Its genes comprise a proper subset of the 106
genes targeted in capture assay 3.
In assessing the theoretical capture size of each assay we noted
the lower yield for capture assay 3 (91%) relative to capture assay 1
(98.8%). This is due to the presence of several genes with close
homologs in the genome such as PTEN which has a well known
pseudogene. Capture oligonucleotides for these repetitive gene
sequences tend to be paralog flagged in the Human OligoExome
resource and while their elimination improves target specificity, it




Total number of genes from CCDS 17,049
Total number of ROI sequences 157,624
Average ROIs per gene 9.25
Total ROI bases derived from CCDS (Mb) 44.6
Total number of designed capture oligonucleotides 784,783
Number of captured ROI bases by design for all restriction enzymes 98.3%
Average number of capture oligonucleotides per gene 46
Average number of capture oligonucleotides per ROI 5
Region-of-interest (ROI) is defined as a minimum of the exon and adjacent intronic sequence up to 50 bases from the exon flank.
doi:10.1371/journal.pone.0021088.t001
Table 2. Oligoexome design and flag summary.
Restriction enzyme BfaI CviQI MseI Sau3AI Total per category
Total designed capture oligonucleotides 190,900 191,315 186,011 216,557 784,783
Oligonucleotides with no flag 169,776 171,320 161,813 184,754 687,663
Oligonucleotides - whole genome
W-flag
20,992 19,882 24,021 31,670 96,565
Oligonucleotides – paralog
P-flag
4,915 4,983 4,854 6,179 20,931
Oligonucleotides – Alu
A-flag
290 183 58 460 991
Oligonucleotides - repeat sequence
R-flag
379 379 578 456 1,792
Total flagged capture oligonucleotides per restriction enzyme
(union of all flagged oligos)
21,124 19,995 24,198 31,803 97,120
doi:10.1371/journal.pone.0021088.t002
Highly Multiplexed Targeted Resequencing
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can reduce target coverage. Using improved design algorithms
(data not shown) it is often possible to place the targeting arms
outside of regions of high homology and thus improve the capture
yield for such regions.
Assessment of targeting performance after capture
adjustment
In the initial performance testing of the targeting assay, we
created three separate subpools of targeting oligonucleotides in
equimolar ratios where each oligonucleotide was at a final
concentration of 50 pM in the circularization reaction. Each
subpool was specific for a single restriction enzyme. Normal
genomic DNA (NA06995 or NA07037) was used in the assessment
of the targeting assay. Resequencing was done with an Illumina
GAI or GAII using single short read sequences ranging from 36 to
42 bases. To assess the individual success of each capture
oligonucleotide, the three subpools were sequenced separately.
This prevented overlap among amplicons from different restriction
enzymes, allowing us to assess the success of each capture
oligonucleotide individually. We aligned the resulting sequence
data for each subpool against the reference sequence and
determined the average fold-coverage (FC) for each amplicon
represented in the subpools.
Similar to other approaches used in capturing genomic targets,
there is variable representation of any given captured sequence.
This variation is attributable to the capture efficiency and the
intrinsic properties of the target genomic sequence. To attain a
more uniform distribution among the targeted genomic regions,
we developed an adjustment scheme. Each oligonucleotide is
categorized into one of three performance groups: i) high yield
resulting in an average FC greater than 1,000, ii) medium yield
resulting in average FC between 100 and 1,000 and iii) low yield
resulting in average FC less than 100. For the adjusted capture
subpools, the low yielding oligonucleotides’ concentration was
increased ten-fold while the high yielding were decreased ten-fold.
The final concentration of each oligonucleotide in the circulari-
zation reaction is 5 pM, 50 pM, and 500 pM for the high yield,
medium yield and the low yield groups, respectively. We initially
tested this adjustment scheme on capture assays 1 and 2. After
concentration adjustment, we observed a decrease in the number
of bases with low fold coverage (,100) in both capture assay 1 and
2 (Fig. 1). Specifically for capture assay 2, we also observe a
decrease in the number of bases with high coverage (.1000) thus
narrowing the coverage distribution. Overall, the variation in the
FC distribution decreased compared to the equimolar pools and
capture failures decreased significantly. For example, in capture
assay 2, the effect of the concentration adjustment include a four-
fold decrease in the number of bases with low representation (1 to
10 average FC) and a two fold increase in the number of medium
yield (101 to 1,000 average FC) bases.
Assessing capture performance and specificity
A summary of the perfomance of the three assays is presented in
Table 4. The assay was extremely reproducible as demonstrated in
two separate replicates of the 106-gene capture assay on NA18507
which was conducted with 50 ng (replicate 1) and 80 ng (replicate
2). Because the design is centered on exons we achieve the highest
coverage on exon bases. For example, in capture assay 3 we show
that the median FC over all targeted bases is 367. However, if one
examines only the exon bases, the median FC is 736. Across all
assays, the percentage of all bases with FC above the half median
is 60–65%. We also analyzed the capture specificity of the assay.
We define nonspecific capture as the percentage of all sequences
which do not map to the regions targeted by the capture
oligonucleotides but do align to regions of the human genome
outside of the targets. For the capture assay 3, the average non-
specific capture was 4.6%.
One aspect of our reported results involves the substantial
increase in sequence data across time. During the course of our
study, the total number of mapped bases increased from 40 to
90 Mb in capture assay 1 to more than one Gigabase (Gb) in both
capture assays 2 and 3. The increase in sequence was due to a
combination of improved capture, sequencer hardware improve-
ments (GAI to GAII) and image analysis, base calling, and
alignment software upgrades (SCS 2.2/Illumina Pipeline 1.01 to
SCS 2.6/Pipeline 1.6). As a result of these changes, the proportion
of the target over which we make high confidence SNV calls
remains relatively constant although the target size increases
nearly ten-fold.
To correlate the capture performance as assessed through
average FC of a specific oligonucleotide with its individual physical
characteristics, we analyzed the post-adjustment performance of
Table 3. Description of assays.
Genomic Target Specifications Capture assay 1 Capture assay 2 Capture assay 3
Total genes 10 96 106
Total exons 179 1776 2021
Total exon bases (Kb) 30.446 325.303 362.309
ROI bases: Total exon plus adjacent 50 bases of intron sequence (Kb) 48.141 501.489 562.974
Capture Assay Specifications
Total capture oligonucleotides 360 4,211 4,792
ROI bases: Total exon plus adjacent 50 bases of intron sequence (Kb) 47.554 454.166 512.556
Intron bases not immediately adjacent to exons (Kb) 54.934 367.984 430.453
Total theoretical captured bases (Kb) 102.488 822.15 943.009
Percentage covered genomic targets 98.8% 90.6% 91.0%
Percentage missed genomic target 1.0% 9.4% 9.0%
Annotation of captured region
Repeat masking over exon plus 50 adjacent intron bases (Kb) 0.468 18.078 19.684
doi:10.1371/journal.pone.0021088.t003
Highly Multiplexed Targeted Resequencing
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the targeting oligonucleotides of capture assays 1 and 2. Our
analysis of the average FC for individual oligonucleotides revealed
that i) the amplicon length, ii) GC% content of the targeting arm
flanks and iii) the flap size of overhanging genomic DNA sequence
influenced the performance of the assays (Text S1). For example,
in capture assay 1, 24 amplicons were larger than 800 bases. They
had an average FC ten times lower than that of the 224
oligonucleotides targeting regions of 200 to 600 bases in size. We
observed a similar trend with capture assay 2. High GC content of
an individual oligonucleotide’s sequence specific capture arms also
contributed to poor performance regardless of the genomic
capture size of the individual assay. Oligonucleotides with capture
arm GC content less than 75% had an average FC two times
greater than those oligonucleotides whose capture arms had GC
Figure 1. Adjustment of capture oligonucleotides performance. Pre- and post-adjustment capture oligonucleotides performance of capture
assays 1 and 2 are shown. Capture assay 1’s target size was 102.48 Kb and this intermediate version of capture assay 2 covered 616 Kb. The Y axis
shows the proportions of bases across the target whose fold-coverage can be sorted into each order of magnitude before and after capture
adjustment. Nominally, we opted for a sequencing depth between 100 and 1,000 as an adequate representation. In both assays, the proportion of
bases whose FC is less than 100 drops significantly; in the case of capture assay 2, the number of bases with excessively high FC has dropped
significantly as well.
doi:10.1371/journal.pone.0021088.g001
Table 4. Variant description and assay performance summary.
Genomic targets Capture assay 1 Capture assay 2Capture assay 3
Total genes 10 10 10 96 106 106
Replicate 1 Replicate 2
Assay yield
Sample NA07037 (CEU) NA07435 (CEU) NA06995 (CEU) NA07037 (CEU) NA18507 (YRI) NA18507 (YRI)
Mapped sequence (Mb) 90.007 40.907 87.770 1550.928 1279.549 1081.001
Percentage not captured for assay 3.6% 4.4% 4.0% 7.3% 9.1% 9.1%
Percent above K median fold coverage 63% 64% 64% 62% 60% 60%
Percentage capture coverage 10 or greater 89.4% 85.4% 89.9% 86.7% 85.0% 84.7%
Median fold-coverage for assay 380 151 348 446 367 304
Hapmap SNP comparison
Heterozygotes (resequencing/array) 18/18 (100.0%) 13/14 (92.9%) 16/16 (100.0%) 135/137 (98.5%) 160/171 (93.5%) 155/168 (92.2%)
Homozygotes (resequencing/array) 42/42 (100.0%) 45/45 (100.0%) 46/46 (100.0%) 344/345 (99.7%) 932/946 (98.5%) 924/936 (98.7%)
Odds ratio Infinite 5,318 Infinite 20,104 952 903
Other SNVs annotated in dbSNPs
Heterozygotes 13 11 9 156 162 160
Homozygotes 10 12 11 84 59 58
doi:10.1371/journal.pone.0021088.t004
Highly Multiplexed Targeted Resequencing
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content greater than 75%. The presence of the overhang genomic
flap region also contributed to decreased performance. We
observed a two-fold drop in average FC for oligonucleotides
producing short flaps and a three-fold drop for those producing
longer flaps. In optimizing capture assay 3, these observed
performance biases were significantly reduced (data not shown).
Analysis of the targeted sequencing results also showed that the
Sau3AI-based capture oligonucleotides had more off-target
capture and amplification than did those derived from the other
three enzymes. The number of oligonucleotides with W-, P- and
A-flags was higher in the Sau3AI set. In particular, we discovered
that the consensus Alu sequences contain no MseI, BfaI or CviQI
sites but two Sau3AI sites are present. We verified (Fig. 2) that
these two sites are highly conserved amongst 10,000 consensus
length Alu sequences randomly chosen from the human genome
aligned to each other using MUSCLE v. 3.6 (http://www.drive5.
com/muscle) [18,19]. Thus, when the Sau3AI capture oligonu-
cleotides are used, a large proportion of these Alu restriction
fragments can circularize because of the internal placement of the
restriction sites.
Multiplexing and reproducibility
To investigate the sample-to-sample variability of the entire
capture and targeted resequencing process, we analyzed the results
from three separate 10-gene assays sequenced in separate
sequencing lanes or in multiplexed format with multiple samples
per lane. Multiplexed resequencing of samples relies on indexing
and is particularly useful for increasing the number of samples in a
given sequencing run when high FC is available. We used a four-
plex indexing methodology in which the tag is introduced via the
Illumina sequencing adapters and the tag consists of a single
nucleotide barcode present immediately after the sequencing
primer. After the base calling process and alignment, the mapped
sequence reads are separately binned based on the barcode. Using
single reads and 1-base barcodes (allowing 4-plex indexing) the
false assignment of barcode sequence (e.g. ‘‘incorrect index
assignment’’ rate) is approximately equal to the sequencing error
rate per base (0.5–1% in these samples). We determined that an
incorrect index assignment rate of up to 1% does not pose
significant problems in terms of accurate genotyping. In the
Hapmap genotype comparison we present below, for the true
positive heterozygote cases we call, the second allele base
percentage is greater than 13%. Below that number, our quality
controls metrics eliminate these potential variant calling errors. If a
sample containing a homozygote variant is incorrectly indexed
and assigned to a different sample, the introduction of the false
homozygote will only contribute 1% of the reads to the other
sample. As an additional error control, we used barcode indexing
on both ends of a mate pair sequences. This dual indexing strategy
reduces the incorrect indexing assignment to 0.1%. This low
indexing error rate is important in certain applications such as
identification of quasi species in viral populations.
In both the single and the multiplexed cases, the median
normalized log FC at each base position is superimposable for all
Figure 2. Evaluation of Alu sequence in non-specific capture. Ten-thousand consensus length (297 bases) Alu sequences were randomly
selected and aligned. The percentage of Alu sequences containing MseI, BfaI, SauIIIA and CviQI sites along the multiple alignment positions is shown.
The four most prevalent restriction sites are SauIIIA sites. The two most frequent amongst these are present in 50 to 75% of the Alu sequences. We
note that the alignment sequence is much longer than many individual Alu sequences because of insertions and deletions.
doi:10.1371/journal.pone.0021088.g002
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three family members over the entire length of a typical targeted
region (Fig. 3). Sharp transitions in FC occur where the capture
oligonucleotides begin and end (e.g. around positions 150, 550 and
1,000). This is expected as the FC represents the sum of all the
oligonucleotides capturing a given region. The three FC curves are
highly correlated in both panels.
We analyzed the reproducibility of FC across three datasets
derived from three independent 10-gene capture assays of three
CEU individuals. Sequencing was conducted both as simplex with
a single capture sample per lane and multiplex with three samples
sequenced in a single lane. After alignment, total sequencing
coverage was median normalized. Median and average values
were calculated for all six samples (Text S1). Correlations between
simplex datasets are shaded in green and correlations between
multiplex dataset are shaded in purple. The Pearson’s correlation
between all pair wise combinations of the six datasets was
calculated. The average correlation between multiplexed se-
quenced datasets is slightly higher (0.96) than between simplex
lanes (0.94) for these three samples.
SNV analysis of targeted resequencing data
As an additional check of our capture assay performance, we
compared our SNV calls from the targeted resequencing data to
the reported Hapmap data for the samples we sequenced (Table 4).
For capture assay 1, we have perfect concordance with Hapmap
genotype data in CEU individuals NA07037 and NA06995. In
NA07435, we have a single false negative heterozygote. In capture
assays 2 and 3, the SNV discovery sensitivities range between
92.2% and 98.5% while the specificities range from 98.5% to
99.7%. The target size and assay yields are comparable between
the two experiments. In addition to the Hapmap SNP genotypes,
we detected other heterozygote and homozygote variants in the
CEU individuals in the 10-gene capture assay. The majority of
these variants are reported in dbSNP (Table 4). All novel variants
are listed in Text S1. A similar trend was also observed for the
larger capture assays.
A complete genome sequence of NA18507, a Yoruban
individual, was published by Bentley et al. [1]. We analyzed
NA18507 with two separate replicates of capture assay 3, which
covered 943 Kb, and we compared our results to the genotype
calls reported from the full genome sequence. For replicate 1,
we detect 582 variants in common with Bentley et al., 89% of
which are in dbSNP, the remainder being novel variants. To
assess additional variants unique to our sequence data we
adopted the exact same procedure as reported by Bentley et al.,
which involves filtering short read misaligned repetitive
sequences [1]. This led us to call 28 additional SNVs not called
by Bentley. Among these 28 variants, 18 are present in dbSNP
(65%). We conducted Sanger sequencing for additional
confirmation on the remaining 10 possible variants. We
confirmed that four of these were heterozygotes by Sanger
sequencing and six were not. Likewise, replicate 2 was nearly
identical in terms of the SNVs we identified.
Insertion and deletion analysis
Detection of insertions and deletions (indels) from single short
read sequences lacking a mate pair is extremely challenging.
Further complicating indel detection, our fragmentation method
involves random concatenation of the captured material
followed by sequencing library preparation. While this method
provides adequate FC over the targets, it essentially precludes
the use of mate pairs for identifying indels since mate pairs from
a given Illumina sequence cluster have a high probability of
coming from different captured amplicons. As a solution for
identifying indels from single reads less than 50 bases, we
aligned the sequence data with the Illumina alignment program,
Figure 3. Comparison of targeted resequencing of independent samples. We show an example of a 1,049 base captured region, occurring
between coordinates 11096583 and 11097631 of chromosome 1. The fold-coverage from the three samples has been normalized by taking the ratio
of fold-coverage at each position to the median depth for the sample, and then taking the log10 of that ratio. Purple lines indicate a capture
oligonucleotide’s target. The exons are indicated by the blue lines. Vertical lines, extending from the beginning and end of each captured amplicon,
show that the discontinuities in depth are associated with the ends of captured targets.
doi:10.1371/journal.pone.0021088.g003
Highly Multiplexed Targeted Resequencing
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21088
Eland v2 (Text S1). This recent version of Eland does simple
indel detection by default using a gapping procedure, and could
only be implemented on the later sequencing runs. Eland v2
introduces a gap when both the following conditions are met: i)
the gap reduces the number of mismatches by 5 compared to
the corresponding non-gapped alignment and ii) the ratio of
mismatches given no gap to mismatches given a gap is at least 3
to 1. Therefore, the size of a detected indel is closely tied to the
length of the sequence read and our short length handicaps the
detection. Using a high specificity set of criteria on the 106-gene
capture assay, we called ten indels from NA18507 among which
six are listed in dbSNP and all are also listed in Bentley et al [1].
We note that before filtering to our desired level of stringency,
our alignment had reported 51 of the 87 indels noted by Bentley
et al. in the same overlapping target region. For NA07037 with
capture assay 2, we found five indels all of which are listed in
dbSNP129. In the case of our matched normal - tumor
colorectal cancer pair, no somatic indels specific to the tumor
were identified.
Mutation discovery from analysis of a matched normal
tumor pair
We developed another analysis procedure for determining
somatic mutations from a matched normal colorectal adenocar-
cinoma pair using capture assay 3. Here, we determine the
difference in the percentage of FC represented by the variant
base between the two sequenced samples. We determine the
standard error (SE) of the difference between the matched
samples and calculated a 95% confidence interval. The
procedure is applied independently to data from the forward
and the reverse reads, as described for the SNV discovery, and we
only consider the tumor specific variants where there is double
strand confirmation. In the analysis of a colorectal matched pair
(2950N, 2951T) we identified multiple cancer mutations (Table 5).
These included mutations in KRAS and APC, two somatic genetic
changes frequently observed in colon cancer. Of particular
interest is a KRAS gene mutation occurring in codon 12 (G12D)
which is a hot spot mutation commonly identified in colorectal
cancer [20]. Approximately 90% of the activating mutations are
found in this particular codon, which represents a highly specific
mutation for colorectal carcinoma [21]. Several groups have
recently validated that KRAS mutations are a negative predictor
of colorectal carcinoma response to monoclonal antibodies (e.g.
panitumimab and cextuximab) targeting epidermal growth factor
receptor (EGFR) [22,23].
Discussion
We have successfully developed an integrated targeted rese-
quencing approach using selective genomic circularization. Our
capture approach is geared towards resequencing gene subsets
smaller than the scale of exome sequencing but larger than can be
done efficiently with simplex PCR. Our method is most
appropriate for applications where: i) low amounts of input
DNA are available, in the range of tens of nanograms, ii) the target
size is on the order of 1 Mb and potentially higher, iii) the number
of samples assayed exceeds 100 and iv) high sequencing coverage
is needed for improved sensitivity. We also developed the Human
OligoExome resource (http://oligoexome.stanford.edu) that en-
ables researchers to download capture oligonucleotide sequences
and create their own customized capture assays. While exome
sequencing has become commonly available, there are numerous
applications and studies which oftentimes only require smaller
scale of targeted resequencing such as the clinical analysis of
Mendelian disorders showing genetic heterogeneity, the confir-
mation of mutations in newly discovered cancer genes from
genome surveys and deep resequencing of loci identified by
genome wide association studies.
In this initial application, we demonstrate that we can assess up
to one Mb with over two thousand exons derived from in silico
sequences for capture oligonucleotides found in the Human
OligoExome resource. Capture success, as defined by a minimum
level of ten-fold-coverage for a given target, was generally greater
than 85%. We applied these custom-designed capture assays on
both normal diploid genomic DNA and cancer samples. We
believe that the capture size can be increased significantly, and are
working to expand the assay capacity.
Our approach has low genomic DNA requirements; specif-
ically, we tested a minimum starting amount less than 100 ng.
To determine the performance reproducibility with low DNA
template amounts, we assessed replicate NA18507 samples using
50 and 80 ng and discovered that the sensitivity and specificity
of SNV discovery were essentially the same. This low DNA
requirement makes our capture assay particularly useful for
sequencing clinical samples where cellular quantities are limited,
such as small biopsy samples and aspirates used in tissue
diagnosis of cancer. For many applications, the low starting
amount of genomic DNA template eliminates the need for
whole genome amplification. The low genomic DNA require-
ments of our method is in contrast with the higher amounts
required for commercially available exome capture methods
such as SeqCap from Nimblegen [11] or SureSelect from
Table 5. Tumor specific mutations in matched normal tumor pair.







Fraction of sequence reads with
the mutation
TNNI3K 1 Exon 20 g.ch:1:74677879G.A c.2047G.A none 31.7% 0.7%
APC 5 Exon 15 g.ch:5:112201816C.T c.2646C.T none 36.4% 1.9%
BAI3 6 Intron 14–15 g.ch:6:69842382G.A NA NA 32.8% 0.3%
BRAF 7 Intron 17–18 g.ch:7:140081065A.G IVS18+25A.G NA 25.8% 0.0%
KRAS 12 Exon 1 g.ch:12:25289551C.T c.226C.T G12D 33.3% 0.9%
NAV3 12 Intron 9–10 g.ch:12:76939845C.A NA NA 25.9% 5.0%
doi:10.1371/journal.pone.0021088.t005
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Agilent [12], both of which require starting microgram amounts
of genomic DNA.
We assessed the on-target specificity of capture of our assays and
found it to be high. In capture assay 3, only 4.6% of the sequences
appear to be derived from non-targeted regions of the human
genome. On-target specificity is mediated by several factors,
including the requirements for both capture arms to anneal to
their complementary genomic target sequences. The capture arm
adjacent to the restriction site must precisely anneal because the
ligation of the vector oligonucleotide to the genomic DNA requires
a precise junction for the ligase reaction to be completed. We
demonstrated that the addition of uracils to the capture and vector
oligonucleotides is extremely useful in eliminating excess oligonu-
cleotides by means of a uracil-deglycosylase after the genomic
circularization.
Our assay’s capture efficiency can be adjusted based on
individual oligonucleotide concentration changes that are readily
handled by standard laboratory robotics. We can alter variance
among captured targets by simply diluting or increasing the
concentration of a specific oligonucleotide. Given that the
capture assay requires a low concentration of each individual
oligonucleotide, typically 5 to 500 pM in 20 ul reaction volumes,
a traditional oligonucleotide synthesis typically yielding 10 nM of
material has the potential to provide assays for a large number of
samples (e.g. up to 106 assays for oligonucleotides used at
500 pM). The low oligonucleotide requirement significantly
reduces the overall cost of the capture assay and as such, reduces
the cost of targeted resequencing in large population genetic
studies that could involve hundreds or thousands of samples. We
also conducted a cost analysis of the method and using an
assumption of an analysis of 1,000 samples our overall (enzymes,
disposables and oligonucleotides) cost per sample was approxi-
mately $75 (Text S1).
Given that the capture occurs in solution, we believe that
automating the assay for increased sample throughput should
prove to be straightforward. We also demonstrated that indexing
of the different samples is a practical solution for increasing the
number of samples per sequencing lane. The success of indexing
shows the practicality of this approach in targeted resequencing of
clinical populations. Reproducibility of the assay was excellent as
demonstrated by comparing simplex to multiplexed sequencing
samples.
We used an Illumina Genome Analyzer to conduct our
resequencing and developed a SNV discovery method with high
levels of statistical confidence based on single short read sequences
less than 50 bases in length. The application of forward and
reverse strand confirmation and repeat masking facilitated highly
accurate SNV discovery. Our sensitivity improved dramatically
during the course of development because of radical improve-
ments made in the capture assay and the remarkable increases in
sequencer output. We anticipate that using longer reads should
further improve our SNV discovery specificity. Longer reads will
also facilitate indel detection, which was severely hampered by the
single short reads that we used.
Materials and Methods
Genomic DNA samples
Genomic DNA for NA07037, NA06995, NA07435 and
NA18507 was obtained from the Coriell Institute for Medical
Research (Camden, NJ). In the case of matched normal and
primary tumor pairs, genomic DNA was extracted from a
matched normal tumor colorectal cancer pair (2950/2951) by
using the DNAeasy Tissue Kit (Qiagen) following the manufac-
turer’s protocols. All patient material was obtained with informed
consent from the Stanford Cancer Center and the study was
previously approved by the institutional review board at Stanford
University School of Medicine.
Capture oligonucleotide design
We utilized a novel bioinformatic design process, referred to as
TargetedOligoDesign, which enabled us to design targeting
oligonucleotides for the entire CCDS exon definition set. This
represents a significant advance over our previous design process
[24]. The Stanford Human OligoExome dataset and the capture
assays described here used CCDS build release 20080902 (ftp://
ftp.ncbi.nlm.nih.gov/pub/CCDS/archive/Hs36.3/), human ge-
nome build NCBI 36.3 (ftp://ftp.ncbi.nlm.nih.gov/genomes/
H_sapiens/) and dbSNP Build ID 129 (http://www.ncbi.nlm.
nih.gov/SNP/) as the polymorphism reference data set. Briefly,
TargetedOligoDesign uses as its inputs the genomic coordinates’
ROI, which encompasses exon boundaries, adjacent intronic
sequence and known SNPs. It takes into consideration the
sequence of the target region, and the recognition site sequence
of the restriction enzyme being tested. We used four restriction
enzymes (MseI, BfaI, SauIIIA or CviQI), all of which recognize 4 bp
sites. The TargetedOligoDesign program takes into account three
factors. First, at least one end of the probe oligonucleotide is
positioned adjacent to a restriction site in the target region, in
order to mediate circularization. Second, the entire targeted
region must be less than 800 bases in length in order to facilitate
efficient circularization and amplification of the ROI. Third, the
oligonucleotide’s capture arms must not hybridize to known SNP
positions. Initially, TargetedOligoDesign designs a probe to
capture an entire ROI if the amplicon is less than 800 bases in
length. The oligonucleotides’ capture arms are designed to
hybridize directly 39 of the 59 restriction site and 59 of the 39
restriction site in the target region. In cases where the resulting
amplicon is greater than 800 bases in length, one capture flank is
designed to hybridize to the boundary of the ROI, while the other
target specific region continues to hybridize directly to the inside of
the restriction site, creating a flap of external sequence that can
later be cleaved using the exonuclease activity of Taq polymerase
(Text S1). The strand targeted by the capture oligonucleotide is by
the structure of the circularized intermediate. When one or more
restriction sites internal to the ROI are present, TargetedOligoDe-
sign will design multiple probes that tile the region.
Annotation of oligonucleotides with quality control
features
We analyzed the sequences of all oligonucleotides’ capture arms
in order to identify potential issues that might cause failures or off-
target capture. Four different quality control factors were reviewed
for each oligonucleotide and any oligonucleotides that failed to
pass them are annotated with flags. First, if one or the other of the
20 base capture arms from a single oligonucleotide is present more
than once in the human genome sequence, the oligonucleotide is
designated with a ‘‘W’’ flag. Second, if both capture arms are
duplicated in the human genome and duplicate capture arms for a
given oligonucleotide are within 1 Kb distance of one another and
in phase, the oligonucleotide is designated with a paralog ‘‘P’’ flag.
Third, if the outer 14 bases of either capture arm perfectly match
an Alu consensus the oligonucleotide is tagged with an ‘‘A’’ flag.
Fourth, if the same outer 14 bases match any other repeated
sequence (e.g. not an Alu) present in a consensus repeat list derived
from Repbase, a data set of human genome repeats [25,26], that
oligonucleotide is designated with a ‘‘R’’ flag. The comparison
against the human genome was conducted with SeqMap [27] run
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against each human chromosome (e.g. seqmap 1 input.fa
hs_ref_chr1.fa output_vs_1/output_statistics), which identifies
the number of perfect matches and single mismatch alignments
separately. The comparisons against consensus repeat sequences
used in the assignment of the A and R flags are performed using
simple string comparison functions in Matlab.
Stanford Human OligoExome database
The Stanford Human OligoExome resource (oligoexome.stan-
ford.edu) runs on a 262.27 GHz Quad Core Intel Xeon E5520
server, with 24 GB memory, and Ubuntu 9.10 operating system.
The web application is implemented in Ruby on Rails 2.3.8,
running under Passenger 2.2.15. The underlying database is
MySQL 5.0.42 community edition, which is hosted on a separate
database server. Query and data download is via any current web
browser. Recommended browsers and versions are: Internet
Explorer 7.0+, Firefox 3.0+, Safari 5.0+, Chrome (any version).
Capture assay method
After creation of an in silico data set of 80-mer oligonucleotide
designs for the exons within CCDS, we selected those which
covered the sets of genes as previously described. All oligonucle-
otides were synthesized at the Stanford Genome Technology
Center and pooled based on those oligonucleotides specific to each
restriction enzyme. This resulted in three separate pools for each
capture assay. The capture oligonucleotides are described in Text
S1. The universal vector sequence and primers are described in
Text S1. The 10-gene capture assay was performed as described
previously [14]. In the case of capture oligonucleotides specific for
Sau3AI, DpnII, a Sau3AI isoschizomer that recognizes the same
palindromic sequence, was the actual enzyme used for restriction
digests. For capture assays 2 and 3, we further optimized the
protocol to reduce the input genomic DNA requirement and
increase the total length of the targeted genomic regions. Briefly, a
total of anywhere from 50 to 250 ng human genomic DNA was
digested to completion with 3 to 5 units of MseI, BfaI, DpnII or
CviQI restriction enzyme (New England BioLabs). Subsequently,
one third of each digestion was combined with 2.5 unit each of
Ampligase (Epicentre Biotechnologies) and Taq polymerase plus
50 pM each of the capture oligonucleotide pool and the vector
oligonucleotide at equimolar concentration with the capture
oligonucleotide pool. The reactions were first denatured at 95uC
for 5 minutes and then subjected to 10–15 cycles at 95uC for
1 minute, 60uC for 45 minutes, and 72uC for 15 minutes. Under
these conditions, the captured genomic regions formed partially
double-stranded circles via oligonucleotide-mediated nick ligation.
Uracil excision enzymes (Epicentre Biotechnologies), at 1 unit per
reaction, were used to linearize the circles and degrade excess
targeting and vector oligonucleotides. After a brief purification
using the Spin-20 columns (Princeton Separations), the captured
DNA pool was amplified by PCR (98uC for 30 seconds followed
by 36–37 cycles at 98uC for 10 seconds, 65uC for 30 seconds, and
73uC for 30 seconds) using Phusion Hot Start High-Fidelity DNA
polymerase (New England BioLabs) and non-target specific
common primers that are homologous to the vector oligonucle-
otide.
After purification using the Fermentas PCR Purification kit,
0.5–1 mg PCR products per sequencing library were ligated to
each other using T4 DNA ligase (New England BioLabs). For
capture assays 2 and 3, the concatenated amplicon DNA was
fragmented using the Bioruptor (Diagenode), a probe-free
sonication device. Capture assay 1 assay was fragmented with
enzymatic DNAseI treatment. We used a 1:400 dilution of
DNAseI (2000 U/ml) (New England Biolabs) in 50 mM Tris
pH 7.5, 10 mM MnCl2, and 50 mg BSA. A volume of 100 ml of
the diluted DNAse solution was added to the concatenated
material and incubated at 37uC for 10 minutes. After 10 minutes,
the reactions were terminated by adding 6 ml of 0.5 M EDTA on
ice, followed by a 10 minute 75uC inactivation. Subsequent
sequencing library preparation was essentially as described in [28]
with minor modifications. For the ‘‘A’’ tailing step prior to ligation
to the adapters, we used Taq polymerase for improved efficiency
and shorter reaction time [29]. Size selection of the sequencing
libraries in the range of 200–300 bp was accomplished by using
the 2% SizeSelect E-Gel (Invitrogen).
Illumina sequencing and simplex PCR – Sanger
sequencing validation
Resequencing was conducted with an Illumina Genome
Analyzer I and II. The samples were sequenced according to the
manufacturer’s specifications. Images were collected and after the
run, image analysis, base calling and error estimation were
performed using Illumina sequencing software (version 2.2.195
through version 2.6.26) and analysis pipeline software (1.01
through 1.6). For capture assay 1, samples were sequenced in 36
single-read cycles, analyzed with pipeline 1.01 and aligned using
MAQ (7.1) with default parameters –n 2, -e 70. For capture assay
2, samples were sequenced in 42 single-read cycles, analyzed using
Illumina RTA 1.5.35 and aligned with Eland, from Illumina
software analysis pipeline version 1.5. For capture assay 3, samples
were sequenced in 42 paired-end cycles, analyzed using Illumina
RTA 1.6.32 and Eland v2, pipeline version 1.6. A PhiX control
lane was used for all image analysis. Alignments used default
parameters. Double-stranded Sanger sequencing on amplified
exons was carried out on a number of variants as confirmation.
Standard PCR and Sanger sequencing was performed similarly to
as presented in Liu et al. [30]. For the validation of novel SNVs,
the gene specific portion of each primer pair used in Sanger
sequencing was derived from a previously published list of primers
[8]. Each forward and reverse primer was tailed at its 59end with
the M13 universal forward and reverse sequences respectively.
Capture assay adjustment
To evaluate the performance of individual targeting oligonu-
cleotides, we assayed normal genomic DNA samples (NA07037
and NA06995) and sequenced the three enzyme-based sub-pools
on separate lanes. For each capture oligonucleotide, using the
sequence alignment data we calculated the average fold-coverage
per base achieved over the entire length of the resulting amplicon.
For variant discovery purposes, we assumed that an average FC
ranging from 100 to 1,000 was an optimal performance range with
FC’s less than 100 or greater than 1,000 being too extreme for
efficient accurate variant discovery and use of sequence capacity,
respectively. We used a Biomek robot (Beckman-Coulter) to
dispense the oligonucleotides for the normalized reaction with
concentration for each oligonucleotide listed in Text S1.
Repeat masking
Given the issues with aligning short sequences to repetitive
regions and the potential for resulting false SNVs, we developed a
repeat masking procedure tailored specifically to short reads. With
this capture assay system, repeats can be generated either i) by
repetitive elements in the intronic regions adjacent to the exons or
ii) within the exons either by repetitive motifs or by paralogs or
pseudogenes which have sequence similarity to the primary
targeted exon. Using the target reference sequence, we created a
series of 14 base sequences via a one base increment tiling across
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the entire genomic target interval. We determined whether these
14 base tiles mapped to a list of consensus Repbase repetitive
elements derived from the human genome (http://www.girinst.
org/repbase) [25,26]. Using sequence data generated from
Hapmap individuals, we discovered that tile sequences shorter
than 14 bases eliminated true SNVs while tile sequences longer
than 14 bases produced a substantially higher number of false
positives. If a specific tile has a perfect match to a sequence of a
repetitive element, each of the coordinates within the tile receives a
score of 1. Additional perfect matches of overlapping tiles are
added to each base coordinate to create a summary repeat
masking score for every genomic coordinate within the target. To
address the issue of repeats not annotated by Repbase, we also
determined whether short sequences from a specific target region-
of-interest were represented multiple times in the human genome,
as may occur in pseudogenes. For this additional repeat masking
procedure, we use the same reference sequence and increase the
tile size to 36 bases given that we are now comparing to a much
larger sequence. This procedure results in a quantitative genome
repeat masking score for each base position. The comparison
against the human genome was conducted by running SeqMap
[27] against each human chromosome (e.g. seqmap 1 input.fa
hs_ref_chr1.fa output_vs_1/output_statistics), which identifies the
number of perfect matches and single mismatch alignments
separately. The results of both repeat masking procedures were
combined as a logical ‘‘OR’’ for our analysis. Any genomic
reference coordinate which is not zero in either repeat masking
score or genome masking score was eliminated from subsequent
SNV discovery.
Detection of SNVs
For SNV detection of our targeted resequencing data, there are
multiple methods available. We tested four methods and
compared the results to determine their performance with our
capture sequence data against Hapmap genotypes from the
capture region. These include MAQ [31], the SAMtools
implementation of the SOAPsnp model [32], the Genome
Analysis Tool Kit (GATK) [33] and our own SNV detection
method which was adapted for this targeting assay metrics.
Comparison to the Hapmap genotype results indicated that the
accuracy of our calling algorithm is 98%. This accuracy is similar
to that of MAQ (97%), GATK (96%) and SOAP (97%). Given the
comparable performance among all four SNV callers and we
opted to use our method as described below.
For MAQ, each of the paired-end reads was aligned separately
using default values: maq map (-n 2 -e 70); they were combined
with the merging function: maq mapmerge. The consensus was
generated using default maq assemble on the combined map file to
produce a cns file, and then maq cns2view was run on the cns file
in order to produce a list of calls at all positions. For other
methods, the first step taken was aligning the concatenated list of
paired-ends reads (i.e. each read treated as a single end) using
BWA, a Burrows-Wheeler aligner. The command used was bwa
samse, with default parameters. The two methods which used this
index were SAMtools and GATK. SAMtools (http://samtools.
sourceforge.net) was run using the SOAPsnp model developed for
the aligner suite SOAP (http://soap.genomics.org.cn) as a SNP
caller. The steps taken were: samtools pileup -avcf, to get variants
only (-v) based on consensus (-c). Requiring calls at every position
led to a much higher number of errors. Therefore we required a
depth of at least 10 and no limitation on the maximum fold
coverage with the following: samtools.pl varFilter -d 10 -D
10000000. The results were then filtered to remove calls with
quality score below 20. GATK is a set of tools developed at the
Broad Institute (ftp://ftp.broadinstitute.org/pub/gsa/GenomeA
nalysisTK/), which includes SNV caller. As a first step, the
Unified Genotype element of GATK was used with default quality
score (-stand_call_conf 50.0) and specifying the platform as solexa
(–platform SOLEXA) in order to call SNPs: java -jar GenomeA
nalysisTK.jar -I input.bam -R ref.fa -T UnifiedGenotyper -varout
GATKsnpCalls.vcf -stand_call_conf 50.0 -S SILENT –platform
SOLEXA. Putative SNPs were then filtered according to metrics
recommended on the GATK wiki (http://www.broadinstitute.
org/gsa/wiki/index.php/): java -jar GenomeAnalysisTK.jar -T
VariantFiltration -R ref.fa -o snpCalls.filtered.vcf -B variant,VCF,
GATKsnpCalls.vcf –clusterWindowSize 10 –filterExpression
‘‘AB.0.75 && DP.40 || SB.20.10’’ –filterName ‘‘Standard-
Filters’’ –filterExpression ‘‘MQ0.=4 && ((MQ0/(1.0 *
DP)).0.1)’’ –filterName ‘‘HARD_TO_VALIDATE’’. In particu-
lar, –clusterWindowSize 10 flags cases where there are 3 or more
SNPs within 10b of one another.
For our own SNV procedure, our algorithm takes into account
i) FC at the variant base call, ii) appearance of the variant base
call on complementary forward and reverse strand reads
(hereafter called ‘‘double-strand confirmation’’) and iii) repeat
masking of repetitive sequences, which can introduce false
positive variants. In our SNV analysis process, for each
coordinate position in the reference sequence, the number of
calls of each base is first counted, both matches and mismatches.
This becomes a mapped sequence matrix consisting of the
chromosome coordinate of the reference and the fold-coverage of
each base call (i.e. the number of A, C, G and T base calls). We
developed an analysis pipeline for variant detection using this
mapped sequence matrix as input. Let fP(b,b’) : b,b’~
A,C,G,Tg be the matrix of probabilities of observing b’ when
the true base is b. Let X~fX (b) : b~A,C,G,Tg be the fold-
coverage for a given base at a specific coordinate position. Under
the null model where the reference coordinate is homozygous
base b, X should be multinomial with probability distribution
p0(b’)~P(b,b’) for b’~A,C,G,T . Under the alternative model
where the position is heterozygous with 50% base call b1 and









In reality, we do not know what the true underlying base is, but
the most frequently observed base at the position (i.e. the base
with the highest fold-coverage (b1) at any given position) is
typically the true base call. If the position is heterozygous, then
the two bases with the highest (b1) and second highest (b2) fold-
coverage usually represent the two alleles. The log likelihood ratio















Using the forward and reverse complementary reads separately,
we compute the likelihood ratio statistic LFi , L
R
i for each position
i. In the first pass, we propose as candidates all potential SNV
positions where both the forward and reverse strand likelihood
ratio statistics are higher than a certain threshold:
S~fi : LFi wt and LRi wtg, ð2Þ
where t is a user-chosen threshold. Requiring both the forward
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and reverse strand confirmation of a variant filters out many
errors that are specific to the sequence processing. Subsequently,
all positions in S that lie in repeated regions of the genome are
repeat masked.
The probability matrix P(b,b’) can be computed by tabulating
the fraction of times b’ is read, when the most frequent base is b,
over all positions in the sequenced region. Since we assume only a
very small fraction of total positions are heterozygotes, the true
heterozygotes contribute little to the fraction. For greater
accuracy, the process can be iterated; that is, after excluding
the heterozygotes identified using P(b,b’) computed from all
positions, P(b,b’) can be recomputed, and used to re-compute the
likelihood scores.
Indel detection
To determine the presence of indel variants from single
sequence reads of less than 50 bases, we aligned the sequence
data with Eland2, an alignment application available with
version 1.6 of the Illumina Genome Analyzer software. Based
on our capture assay of NA18507, which had complete genome
sequencing data available, we developed a procedure to
eliminate false positive indels. First, we required sequence data
from at least two breakpoints in both forward and reverse
alignments, where breakpoint is the first position of a read.
Second, the indel sequence had to have FC at the 59 position
greater than 50. Third, we required that a sequence containing
the indel fail to align against the genome with less than 3
mismatches. This minimizes the risk that an off-target captured
sequence would be falsely called as an indel. Eland2’s indel
detection is heavily dependent on the read lengths of the
sequences involved, however, so the relatively short sequencing
lengths of the assays in this paper preclude extensive indel
discovery.
Detection of mutations in matched normal tumor sample
For identifying somatic mutations from matched normal and
tumor samples, we required a more sensitive test to detect somatic
and cancer-specific SNVs. We developed a method based on t-test
statistics and confidence intervals for targeted resequencing of
matched tumor normal pairs using double-strand confirmation.






T ) be the base counts in






T ) be the base counts in the matched
normal. Let CN and CT denote respectively the fold-coverage in



















D is the difference in count of the base b between the tumor and
the normal. If this position were a homozygote for the same base
in both normal and tumor, then D would be small in absolute
value. If this position were a homozygote in normal that has
turned into heterozygote in the tumor, then D would be a large
positive fraction. This method does not detect heterozygote to
homozygote shifts as in regions of loss of heterozygosity, which we
identify by first isolating the heterozygous positions in the normal
and then computing the difference in the counts between the two
alleles in the tumor.
The confidence interval for D factors in the coverage in both
the normal and tumor samples. If the coverage is high in both
samples, then the confidence interval is narrow. If either sample
has low coverage, then the standard error in D is large, leading
to a wide confidence interval. The equation for the standard









With sufficient depth, D is approximately t distributed. The
(1{a) confidence interval for D can then be computed based on
the quantiles of the appropriate Student-t distribution. With the
confidence intervals computed, the filtering rule is based on the
(1{a) confidence interval and a minimum acceptable value
Dmin for the absolute change jDj. We report positions where
Dw0 and the lower confidence interval is above Dmin, or Dv0
and the upper confidence interval is below Dmin. In this study
we have used Dmin~:1 and a~0:5.
Supporting Information
Figure S1 The selective genomic circularization pro-
cess. Genomic DNA is digested with one of several possible
restriction enzymes. The restriction digest is mixed with a pool
of targeting oligonucleotides and a single 40 base oligonucleo-
tide vector. Each targeting oligonucleotide has two 20 base
capture arms complementary to genomic DNA. One of the
capture arms is positioned exactly at the end of the restriction
fragment the other arm may be placed internally to the
restriction fragment. The 59endonuclease activity of TaqI
polymerase degrades the 59 extension if present and ligase
circularizes the intermediate. The UDG reaction degrades the
targeting oligonucleotide and linearizes the circle. Double
stranded linear products are then generated by PCR using a
pair of common primers.
(TIF)
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